Tagged with Lif

France European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both the US and China every year; recent data from ING shows that the percentage of global new drug approvals originating…

Hong Kong Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He traces the organisation’s evolution from US-based acquisitions to a protein/peptide and circular RNA vaccine platform built in Hong Kong, explains…

USA Patients and carers with lived experience of a disease have valuable insights to share with physicians and drug developers alike. This is especially true of rare diseases, defined in the US as those that affect fewer than 200,000 people nationwide and which collectively impact over 30 million Americans. For these…

France Stéphane Legastelois has spent 35 years bridging science and business. After founding Indicia, he transitioned to healthcare investing, backing 30 early-stage companies, mainly in Lyon, and now heads up 33 Californie, a boutique investment firm which combines capital with strategic guidance, de-risking start-ups before Series A financing. As he explains,…

LatAm From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that we are poised to become among the most dynamic regions for growth momentum globally driven by multiple factors: among them…

LatAm When it comes to pharmaceutical exports, Latin America has historically been confined to the margins of the global life science industry. In 2023, the region accounted for a mere one percent of worldwide pharmaceutical exports, down from 1.97 percent a decade earlier, despite housing over eight percent of the world’s…

USA Michael Pearlmutter, CEO of the EveryLife Foundation for Rare Diseases (the EveryLife Foundation), brings a deeply personal motivation and commitment to driving meaningful change for the rare disease community. In this conversation, Pearlmutter reflects on the Foundation’s mission, its impact across the rare disease ecosystem, and the evolving opportunities to…

Hong Kong CK Life Sciences, under the leadership of CEO Lance Yuen, is reshaping its identity through a renewed focus on early-stage oncology innovation powered by next-generation cancer vaccines, AI-enabled design and a growing network of regional partnerships. Stable commercial revenues give the organisation unusual freedom to pursue high conviction science, while…

USA Kelly LoBianco, founding director of the Los Angeles County Department of Economic Opportunity, discusses how the agency is driving growth of the region’s life sciences sector. She outlines LA County’s Life Sciences Industry Cluster Strategy and Action Plan, which aims to create 10,000 new industry jobs by 2030 and explains…

Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…

USA Tim Scott, President and CEO of Biocom California, leads the state’s largest and most influential life sciences association at a pivotal moment for the industry. With more than 1,800 members across biotech, pharma, medtech, diagnostics, and research institutions, Biocom California represents the full breadth of the ecosystem. In this interview,…

Denmark Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups. And with life science exports surpassing EUR 23 billion last year…